Nonsteroidal anti-inflammatory drugs and gastroduodenal injury

American Journal of Therapeutics

Volumn 5, Issue 4, 1998, Pages 263-272

  Venkat, Kumar ^a   Brown, Michael D ^a   Barkin, Robert ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Gastroduodenal; NSAIDs; Prostaglandin; Ulcer

Indexed keywords

MISOPROSTOL; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN DERIVATIVE; PROTON PUMP INHIBITOR;

DIGESTIVE SYSTEM INJURY; DRUG INDICATION; DRUG MECHANISM; GASTROINTESTINAL TOXICITY; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROPHYLAXIS; PROSTAGLANDIN SYNTHESIS INHIBITION; REVIEW; UNITED STATES;

EID: 0031830321     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-199807000-00009     Document Type: Review

References (90)

1. Baum C, Kennedy DL, Forbes MB: Utilization of non-steroidal anti-inflammatory drugs. Arthritis Rheum 1985;28:686-692.
2. Anti-arthritic medication usage: 1991. Stat Bull 1992;73: 25-34.
3. McCarthy DM: Non-steroidal anti-inflammatory drug induced ulcers: management by traditional therapy. Gastroenterology 1989;96:662-674.
4. Pawlus HE: FDA Arthritis Advisory Committee meeting: serious gastrointestinal toxicity of non-steroidal anti-inflammatory drugs. Am J Med 1983;31:1450-1451.
5. Edelson JT, Tostesin ANA, Sax P: Cost effectiveness of misoprostol for prophylaxis against non-steroidal anti-inflammatory drug induced gastrointestinal bleeding. JAMA 1990;264:41-47.
6. Armstrong CP, Blower AL: Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987;28:527-532.
7. Pincus J, Griffin M: Gastrointestinal disease associated with non-steroidal anti-inflammatory drugs: new insights from observational studies and functional status questionnaires. Am J Med 1991;91:209-212.
8. Langman MJS: Epidemiologic evidence on the association between peptic ulceration and anti-inflammatory drug use. Gastroenterology 1989;96:640-646.
9. Smith WL, Mamett LJ, Dewitt DL: Prostaglandin and thromboxane biosynthesis. Pharmacol Ther 1991;49:153-179.
10. Eberhart CE, Dubois RN: Eicosanoids and the gastrointestinal tract. Gastroenterology 1995;109:286-301.
11. Jones DA, Carlton DP, McIntyre TM, et al: Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem 1993;268:9049-9054.
12. Dubois RW, Awad J, Morrow J, et al: Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor alpha and phorbol ester. J Clin Invest 1994;93:493-498.
13. Marnett LJ: Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 1992;52:5575-5589.
14. Barkin RL: Cancer pain treatment insights. Pharmacotherapy 1997;17:397-398.
15. Brooks PM, Day RO: NSAID drugs: differences and similarities. N Engl J Med 1991;321:1716-1725.
16. Schoen RT, Vender RJ: Mechanism of NSAID induced gastric damage. Am J Med 1989;86:449-458.
17. Sanders MJ, Ayalan A, Roll M, et al: The apical surface of canine chief cell monolayers resists hydrogen ion back diffusion. Nature 1985;313:52-54.
18. Scheiman JM: NSAIDS, gastrointestinal injury and cytoprotection. Gastroenterol Clin North Am 1996;25:279-298.
19. Estes LL, Fuks DW, Heaton AH, et al: Gastric ulcer perforation, associated with the use of injectable ketorolac. Ann Pharmacol Ther 1993;27:42-43.
20. Carson JL, Strom BL, Morse ML, et al: Relative gastrointestinal toxicity of the non-steroidal anti-inflammatory drugs. Arch Intern Med 1987;147:1054-1059.
21. Silen W: Gastric mucosal defense and repair. In: Physiology of the Gastrointestinal Tract. (Ed. Johnson LR), Raven Press, New York, 1987, pp 1055-1070.
22. 3-transport: characteristics and proposed role in acidity, regulation and mucosal protection. Am J Physiol 1982; 242:G183-G193.
23. Scheiman J, Kraus E, Bonnville L, et al: Synthesis and prostaglandin E2 induced secretion of surfactant phospholipid by isolated gastric mucus cells. Gastroenterology 1991;100:1232-1240.
24. Lacy ER: Epithelial restitution in the gastrointestinal tract. J Clin Gastroenterol 1988;10:72-77.
25. Wallace J: Prostaglandins, NSAIDs and cytoprotection. Gastroenterol Clin North Am 1992;21:631-641.
26. Scheiman JM: Pathogenesis of gastroduodenal injury due to non-steroidal anti-inflammatory drugs: implications for prevention and therapy. Semin Arthritis Rheum 1992;21:201-210.
27. Chen MC, Amirion DA, Toomey M, et al: Prostanoid inhibition of canine parietal cells: mediation by the inhibitory guanosine triphosphate binding protein of adenylate cyclase. Gastroenterology 1988;94:1121-1129.
28. Asako H, Kubes P, Wallace JL, et al: Indomethacin induced leukocyte adhesion in mesenteric venules: role of lipoxygenase products. Am J Physiol 1992;262:G903-G908.
29. Prichard PJ, Kitchingman GK, Walt RD, et al: Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin. Br Med J 1989;298:493-496.
30. Lanas A, Sekar MC, Hirschowitz BI: Objective evidence of aspirin use in both ulcer and non-ulcer upper and lower gastrointestinal bleeding. Gastroenterology 1992; 103:862-869.
31. Laine L, Martin-Sorensen M, Weinstien WM: Non-steroidal anti-inflammatory drug-associated gastric ulcers do not require Helicobacter pylori for their development. Am J Gastroenterol 1992;87:1398-1402.
32. Zinsmeister AR, Carpenter HA, Ahlquist DA, et al: Long term non-steroidal anti-inflammatory drug use and gastro-duodenal injury: the role of Helicobacter pylori. Gastroenterology 1992;102:1899-1905.
33. Graham DY, Lidsky MD, Cox AM, et al: Long term non-steroidal anti-inflammatory drug use and Helicobacter pylori infection. Gastroenterology 1991;100:1653-1657.
34. Jones STM, Clague RB, Eldridge J, et al: Serological evidence of infection with Helicobacter pylori may predict gastrointestinal intolerance to non-steroidal anti-inflammatory drug treatment in rheumatoid arthritis. Br J Rheumatol 1991;30:16-20.
35. Martin DF, Montgomery E, Dobek AS, et al: Campylobacter pylori, NSAIDS and smoking: risk factors for peptic ulcer disease. Am J Gastroenterol 1989;84:1268-1272.
36. Bjorkman DJ, Kimmes MB: Non-steroidal anti-inflammatory drugs and gastrointestinal disease: pathophysiology, treatment and prevention. Dig Dis 1995;13: 119-129.
37. Silvoso GR, Iveky KJ, Butt JH, et al: Incidence of gastric lesions in patients with rheumatic disease on chronic aspirin therapy. Ann Intern Med 1979;91:517-520.
38. McCarthy D, Kurata J, Weinstein WM, et al: Non-steroidal anti-inflammatory drugs and peptic ulcer disease. Ann Intern Med 1991;114:307-319.
39. Bijlsma J, and the Multicenter Group: Treatment of endoscopy negative NSAID induced upper gastrointestinal symptoms with cimetidine: an international multicenter collaborative study. Aliment Pharmacol Ther 1988;2(Suppl):85-96.
40. Armstrong CP, Blower AL: Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987;28:527-532.
41. Larkai EN, Smith JL, Lidsky MD, et al: Gastrointestinal mucosa and dyspeptic symptoms in arthritic patients during chronic non-steroidal anti-inflammatory drug use. Am J Gastroenterol 1987;82:1153-1158.
42. Barner CH, Hirschowitz BJ: Controversies in the detection and management of non-steroidal anti-inflammatory drug-induced side effects of the upper gastrointestinal tract. Arthritis Rheum 1989;32:926-932.
43. Somerville K, Faulkner G, Langman M: Non-steroidal anti-inflammatory drugs and bleeding peptic ulcer. Lancet 1986;1:462-464.
44. Henry DA, Johnston A, Dobson A, et al: Fatal peptic ulcer complications and the use of NSAID drugs, aspirin and corticosteroids. Br Med J 1987;295:1227-1229.
45. Gabriel SE, Jaakkimainen RL, Bombardier C: Risk for serious gastrointestinal complications related to the use of non-steroidal anti-inflammatory drugs. A metaanalysis. Ann Intern Med 1991;115:787-796.
46. Fries JF, Miller SR, Spitz DW, et al: Toward an epidemiology of gastropathy associated with non-steroidal anti-inflammatory drug use. Gastroenterology 1989;96:647-655.
47. Laporte JR, Carne X, Vidai X, et al: Upper gastrointestinal bleeding in relationship to previous use of analgesics and non-steroidal anti-inflammatory drugs. Catalon countries study on upper gastrointestinal bleeding. Lancet 1991;337:85-89.
48. Conn HO, Blitzer BL: Non association of adrenocorticosteroid therapy and peptic ulcer. N Engl J Med 1976;294: 473-479.
49. Piper JM, Ray WA, Daugherty JR, et al: Corticosteroid use and PUD: role of NSAIDs. Ann Intern Med 1991; 114:735-740.
50. Henry D, Dobson A, Turner C: Variability in the risk of major gastrointestinal complications from non-aspirin, non-steroidal anti-inflammatory drugs. Gastroenterology 1993;105:1078-1088.
51. Roderick PJ, Wilkes HC, Meade TW: The gastrointestinal toxicity of aspirin: an overview of randomized controlled trials. Br J Clin Pharmacol 1993;35:219-226.
52. Graham DY: Non-steroidal anti-inflammatory drugs, Helicobacter pylori and ulcers: where we stand. Am J Gastroenterol 1991;10:2080-2085.
53. Petitti DB, Strom BL, Melman KL: Prothrombin time ratio and other factors associated with bleeding in patients treated with warfarin. J Clin Epidemiol 1989;42:759-764.
54. Garcia-Rodriguez LA, Jick H: Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:769-772.
55. Serlin MJ, Breckenridge AM: Drug interaction with warfarin. Drugs 1983;25:610-620.
56. Lanas A, Serrano P, Bajador E, et al: Evidence of aspirin use in both upper and lower gastrointestinal perforation. Gastroenterology 1997;112:683-689.
57. Quimby GF, Bonnie CA, Bustein SH, et al: Active smoking depresses prostaglandin synthesis in human gastric mucosa. Ann Intern Med 1986;104:616-619.
58. Walan A, Bader JP, Classen M, et al: Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med 1989; 320:69-75.
59. Scheiman JM: NSAID-induced peptic ulcer disease: a critical review of pathogenesis and management. Dig Dis 1994;12:210-222.
60. Bradley JD, Brandt KD, Katz BP, et al: Comparison of anti-inflammatory dose of ibuprofen, an analgesic dose of ibuprofen and acetaminophen in therapy of patients with osteoarthritis of the knee. N Engl J Med 1991;325: 87-91.
61. Barkin RL: Focus on tramadol: a centrally acting analgesic for moderate to moderately severe pain. Hospital Formulary 1995;30:321-325.
62. Griffin MR, Piper JM, Daugherty JR, et al: Non-steroidal use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991;114:257-263.
63. Savage RL, Moeller PW, Ballantyne CL, et al: Variation in the risk of peptic ulcer complications with non-steroidal anti-inflammatory drug therapy. Arthritis Rheum 1993;36:84-90.
64. Cryer B, Luk G, Feldman M: Effects of very low doses of aspirin on gastric, duodenal and rectal prostaglandin and mucosal injury. Gastroenterology 1995;108:A77.
65. Roth S, Bennett R, Caldron P, et al: Reduced risk of NSAID gastropathy with non-acetylated salicylate (salsalate): an endoscopic study. Semin Arthritis Rheum 1990;19(Suppl 2):11-19.
66. Dandona P, Jeremy JY: NSAID and gastric side effects: does nabumetone provide a solution? Drugs 1990; 40(Suppl 5):16-24.
67. Lanza FL: Gastrointestinal toxicity of newer NSAIDS. Am J Gastroenterol 1993;88:1318-1323.
68. Frieddel H, Langlry H, Buckely MJ: Nabumetone: a reappraisal of its pharmacodynamic and pharmacokinetic properties and therapy efficacy. Drugs 1986;32:291.
69. Taha AS, McLaughlin S, Stumock RD, et al: Evaluation of efficacy and comparative effects on gastric and duodenal mucosa of etodolac and naproxen in patients with rheumatoid arthritis using endoscopy. Br J Rheumatol 1989;28:329-332.
70. Ehsanullah RS, Page MC, Tidesley G, et al: Prevention of gastro-duodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine. Br Med J 1988;97:1017-1021.
71. Levine LR, Cloud ML, Enas NH: Nizatidine prevents peptic ulceration in high risk patients taking NSAIDs. Arch Intern Med 1993;153:2449-2454.
72. Singh G, Romey DR, Morfeld D, et al: Gastrointestinal tract complications of non-steroidal anti-inflammatory drug treatment in rheumatoid arthritis. Arch Intern Med 1996;156:1530-1536.
73. Taha AS, Hudson N, Trye P, et al: Famotidine for the prevention of gastric and duodenal ulcers caused by non-steroidal anti-inflammatory drugs. N Engl J Med 1996;334:1435-1439.
74. Daneshmend TK, Stein AG, Bhaskar NK, et al: Abolition by omeprazole of aspirin induced gastric mucosal injury in man. Gut 1990;31:514-519.
75. Ekstrom P, Carling L, Wetterhus S: Omeprazole reduces the frequency of gastroduodenal lesions and dyspeptic symptoms during non-steroidal anti-inflammatory therapy. Gastroenterology 1995;108:A87.
76. Karim A: Anti-ulcer prostaglandin misoprostol: single and multiple dose pharmacokinetic profile. Prostaglandin 1987;33(Suppl):298-303.
77. David GR, Pordtran JS, Dojam EZ: Dose response, meal stimulated gastric anti-secretory study of prostaglandin E1 analogs, misoprostol in man. Dig Dis Sci 1988;33:298-302.
78. Wilson DE: Anti-secretory and mucosal protective actions of misoprostol: potential risk in the treatment of peptic ulcer disease. Am J Med 1987;83(Suppl 1A):2-8.
79. Shah K, Price AB, Talbot IC, et al: Effect of long term misoprostol co-administration with NSAIDs. A histological study. Gut 1995;37:195-198.
80. Graham DY, Agrawal NM, Roth SA: Prevention of NSAID induced gastric ulcer with misoprostol: multicenter, double blind, placebo controlled study. Lancet 1988;2:1277-1280.
81. Graham DY, White RH, Moreland LW, et al: Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Intern Med 1993;119: 257-262.
82. Raskin JB, White R, Janinsk R: Misoprostol and ranitidine in the prevention of non-steroidal induced gastric and duodenal ulcer disease. Multi-center trial. Gastroenterology 1992;102:A151.
83. Agrawal NM, Roth S, Graham DY, et al: Misoprostol compared with sucralfate in the prevention of non-steroidal anti-inflammatory drug-induced gastric ulcer. A randomized, controlled trial. Ann Intern Med 1991; 115:195-200.
84. Silverstein FG, Graham DY, Sener JR, et al: Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving non-steroidal anti-inflammatory drugs. Ann Intern Med 1995;123:241-249.
85. Knill-Jones R, Drummond M, Kohli H, et al: Economic evaluation of gastric ulcer prophylaxis in patients with arthritis receiving non-steroidal anti-inflammatory drugs. Postgrad Med J 1990;66:639-646.
86. Hillman AL, Bloom BS: Economic effects of prophylactic use of misoprostol to prevent gastric ulcer in patients taking non-steroidal anti-inflammatory drugs. Arch Intern Med 1989;149:2061-2065.
87. Soll AH: Consensus conference. Medical therapy of peptic ulcer disease. Practical guidelines. JAMA 1996;275: 622-629.
88. Levine JS: Misoprostol and non-steroidal anti-inflammatory drugs: a tale of effects, outcomes, costs. Ann Intern Med 1995;123:309-310.
89. Salter RH: Aspirin and gastrointestinal bleeding. Am J Dig Dis 1968;13:38-52.
90. Duggan JM: Aspirin ingestion and perforated peptic ulcer. Gut 1972;13:631-633.